Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dihydroartemisinin/piperaquine - Chongqing Holley Holding/Medicines for Malaria Venture/Oxford University/Sigma-tau SpA

Next Previous
Drug Profile

Dihydroartemisinin/piperaquine - Chongqing Holley Holding/Medicines for Malaria Venture/Oxford University/Sigma-tau SpA

Alternative Names: Artekin; Eurartekin; Eurartesim; Piperaquine/dihydroartemisinin

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chongqing Holley; Medicines for Malaria Venture; sigma-tau SpA; University of Oxford
  • Developer Medicines for Malaria Venture; sigma-tau SpA
  • Class Antimalarials; Artemisinins; Piperazines; Quinolines; Sesquiterpenes
  • Mechanism of Action Free radical stimulants; Hemozoin inhibitors; Protein synthesis inhibitors; Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malaria
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malaria

Most Recent Events

  • 19 Feb 2021 The Medicines for Malaria Venture announces intention to submit MAA to the EMA for Malaria (In neonates, In infants, In adolescents)
  • 12 Oct 2018 No recent reports on development identified - Phase-II for Malaria (In infants) in Congo, Gambia, Mozambique, Burkina Faso, Tanzania (PO, Fast dissolve)
  • 08 Jul 2015 Sigma-tau SpA completes its phase II trial in Malaria (In infants) in Tanzania, Congo, Mozambique, Gambia and Burkina Faso (NCT01992900)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top